STOCK TITAN

Verrica Q3 loss widens to $12.4M as revenue falls

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Verrica Pharmaceuticals Inc. reported Q3 2026 total revenue of $6.914 million, compared with $14.344 million a year earlier, and a net loss of $12.407 million, versus $274,000. U.S. YCANTH net product revenue was a record $5.697 million, up 11.9% from the prior quarter and 57.9% year over year; license and collaboration revenue was $1.217 million, down from $10.737 million. For the first nine months, revenue was $17.799 million versus $30.485 million, and net loss was $35.242 million versus $9.812 million.

The company said it met pre-defined revenue, growth and operational milestones under its credit facility, unlocking full access to $27.5 million of non-dilutive growth capital. Under its current operating plan, including full utilization of the facility, Verrica said it has sufficient liquidity to fund operations through data readouts for both common-warts trials. Enrollment is complete in the first pivotal Phase 3 trial, and the second has enrolled more than 50% of its current patient target; topline data are expected in Q1 2027 and mid-2027, respectively. Verrica is exploring VP-315 for Gorlin syndrome.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Moderate pointYCANTH product revenue reached $5.697 million, up 57.9% year over year.

Negative

  • Moderate pointQ3 total revenue was $6.914 million, versus $14.344 million a year earlier.
  • Moderate pointQ3 net loss was $12.407 million, versus $274,000 a year earlier.

Filing Explained

At September 30, 2026, Verrica reported $14,394 thousand in cash, $11,636 thousand in net related-party term loans, and $10,940 thousand in R&D funding liabilities; stockholders’ equity was a $5,974 thousand deficit.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Q3 YCANTH net product revenue $5.697 million Three months ended September 30, 2026; up 11.9% from the prior quarter and 57.9% year over year.
Q3 total revenue $6.914 million Three months ended September 30, 2026; $14.344 million in the same quarter of 2025.
Q3 net loss $12.407 million Three months ended September 30, 2026; $274,000 in the same quarter of 2025.
Nine-month revenue $17.799 million Nine months ended September 30, 2026; $30.485 million in the same period of 2025.
Nine-month net loss $35.242 million Nine months ended September 30, 2026; $9.812 million in the same period of 2025.
Cash $14.394 million As of September 30, 2026; $30.147 million as of December 31, 2025.
Credit facility growth capital $27.5 million Full access unlocked after the company met pre-defined revenue, growth and operational milestones; described as non-dilutive growth capital.
Second common-warts trial enrollment More than 50% of the current patient target Enrollment in the second pivotal Phase 3 trial.
net product revenue financial
"record U.S. YCANTH net product revenue of $5.7 million"
Net product revenue is the money a company actually earns from selling its products after subtracting returns, discounts, rebates and other sales-related allowances. It shows the real cash-generating sales performance—like the amount a store keeps after giving change for coupons and refunds—and matters to investors because it drives profitability, helps forecast future cash flow and reveals whether reported sales are sustainable or inflated by temporary price cuts or promotions.
gross to net financial
"improvement in gross to net"
non-GAAP income (loss) from operations financial
"non-GAAP income (loss) from operations"
oncolytic chemotherapeutic peptide immunotherapy medical
"a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy"
immunogenic cell death medical
"to induce immunogenic cell death"
Immunogenic cell death is a form of cell death that not only kills diseased cells (such as cancer cells) but also releases signals that alert and activate the immune system to recognize and attack remaining disease. For investors, therapies that trigger this response can increase the chance of durable, long-lasting treatment effects—like sounding an alarm that recruits security guards—making such drugs potentially more valuable and differentiable in the market.
topline data medical
"topline data from these trials"
Topline data are the initial, high-level results from a clinical study that show whether the main goals of the trial were met, much like the headline of a news story that summarizes the most important point. Investors care because these early outcomes quickly indicate a drug’s commercial potential and regulatory path — positive topline results can boost a company’s value, while disappointing ones can sharply reduce expected future revenue.
Q3 total revenue $6.914 million Compared with $14.344 million in Q3 2025.
Q3 YCANTH net product revenue $5.697 million Up 11.9% from the prior quarter and 57.9% year over year.
Q3 net loss $12.407 million Compared with $274,000 in Q3 2025.
Nine-month revenue $17.799 million Compared with $30.485 million in the first nine months of 2025.
Nine-month net loss $35.242 million Compared with $9.812 million in the first nine months of 2025.
Guidance

Topline data from the first and second common-warts pivotal trials are expected in Q1 2027 and mid-2027, respectively. Verrica said it has sufficient liquidity to fund operations through both readouts under its current operating plan, including full utilization of its credit facility.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much YCANTH revenue did VRCA report in Q3 2026?

Verrica reported $5.697 million in U.S. YCANTH net product revenue in Q3 2026, up 11.9% from the previous quarter and 57.9% year over year. Total revenue was $6.914 million.

Why was enrollment completed in Verrica’s first common-warts pivotal trial?

An interim analysis recommended that no additional patients were needed to power the trial; Verrica said enrollment was completed in August. The second pivotal trial had enrolled more than 50% of its current patient target.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001660334 0001660334 2026-11-12 2026-11-12
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2026

 

 

Verrica Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-38529   46-3137900

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

44 W. Gay St., Suite 400  
West Chester, PA   19380
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (484) 453-3300

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class

 

Trading

symbol

 

Name of each exchange

on which registered

Common Stock   VRCA   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 2.02

Results of Operations and Financial Condition.

On November 12, 2026, Verrica Pharmaceuticals Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2026, as well as information regarding a conference call to discuss these financial results and the Registrant’s recent corporate highlights. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

   Exhibit Description
99.1    Press Release, dated November 12, 2026
104    Cover Page Interactive Data File (formatted as inline XBRL).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Verrica Pharmaceuticals Inc.
Date: November 12, 2026  

/s/ John J. Kirby

  John J. Kirby
  Interim Chief Financial Officer

Exhibit 99.1

Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results

– Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million –

– Enrollment completed in the first of two pivotal trials in the global Phase 3 common warts program, with topline data for each trial expected in Q1 2027 and mid-2027, respectively –

– Company achieved pre-defined revenue, growth and operational milestones under credit facility to unlock full access to $27.5 million of non-dilutive growth capital and further extend cash runway through data readout for both common warts trials –

– Company is now exploring the development of its oncolytic peptide, VP-315, for the treatment of patients with Gorlin syndrome, a rare genetic disease characterized by frequent emergence of basal cell carcinomas –

– Conference call scheduled for Thursday, November 12, 2026, at 4:30 pm ET –

WEST CHESTER, PA – November 12, 2026 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced financial results for the third quarter ended September 30, 2026.

“Verrica made progress in growing our commercial YCANTH business for molluscum contagiosum while advancing our late-stage pipeline for two of the most prevalent skin diseases, and extending our cash runway during the third quarter,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “YCANTH had another record quarter for revenue, and we are now turning our focus to maximize conversion of written to filled prescriptions and ensuring optimal insurance coverage. The efforts that began earlier this year, most notably under our YCanthRx non-dispensing pharmacy option, have matured, and during the quarter we began realizing the benefits of these efforts with improvement in gross to net.”

Dr. Rieger continued, “We are also executing on our label expansion strategy for YCANTH into common warts. In August, we announced the completion of enrollment in the first pivotal trial of our global Phase 3 program in common warts after an interim analysis recommended that no additional patients were needed to power the trial. We have also enrolled more than 50% of the current patient target in the second pivotal trial, and we expect topline data from these trials in the first quarter of 2027 and mid-2027, respectively. Under our current operating plan, including finishing the global Phase 3 program in common warts, and the full utilization of our credit facility, we now have sufficient liquidity to fund operations through data readouts for both pivotal trials of the common warts program. With a prevalence of approximately 22 million patients in the U.S. alone and no FDA-approved prescription drug therapies, we believe that securing a label expansion for YCANTH into common warts could represent a multibillion-dollar commercial opportunity, if approved. Finally, we are now exploring the potential of VP-315 to treat patients with Gorlin syndrome, a rare disease that leads to dozens or hundreds of basal cell carcinomas over the patient’s lifetime, often presenting them with substantial surgical fatigue. We believe our foundational data in sporadic BCC provides promise for the potential benefit of VP-315 to Gorlin patients, and we will provide more details as the clinical protocol and anticipated timelines are finalized. We are excited about our future at Verrica, having built a solid commercial foundation to support promotion of YCANTH for molluscum which we can leverage upon any approval of YCANTH for common warts or VP-315 for BCC or Gorlin syndrome.”


Conference Call and Webcast Information

The Company will host a conference call on Thursday, November 12, 2026, at 4:30 pm ET, to discuss its third quarter 2026 financial results and provide a business update. To participate in the conference call, please use the following information:

Domestic Dial-In Number: Toll-Free: 1-833-419-0865

International Dial-In Number: 1-785-838-9333

Conference ID: VERRICA

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1777570&tp_key=5f6b4ae4b1

The call will be broadcast live over the web and can also be accessed on Verrica’s website: www.verrica.com. A replay will be available for one month in the Events Calendar of the Investors section of the Company’s website.

Business Highlights and Recent Developments

YCANTH® (VP-102)

 

  •  

During the third quarter, the Company recorded YCANTH net product revenue of $5.7 million, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million.

 

  •  

During the third quarter, YCANTH dispensed applicator units totaled 19,135, representing a year-over-year increase of approximately 36% from the third quarter of 2025. On a sequential basis, YCANTH dispensed applicator units decreased approximately 2.5% from the prior quarter. We believe this decrease reflects summer travel seasonality, with both patients and providers.

 

  •  

On September 30, 2026, the Company announced new pooled analysis data from its two registrational Phase 3 trials of YCANTH for molluscum. These data indicated that patients treated with YCANTH achieved complete clearance at a rate approximately four times faster than patients who were treated with a placebo, and three times as many YCANTH-treated patients achieved complete clearance at each treatment visit.

 

  •  

On August 27, 2026, the Company announced completion of enrollment in the first pivotal Phase 3 trial (COVE-2) studying YCANTH for the treatment of common warts and greater than 50% enrollment in the second pivotal Phase 3 trial (COVE-3). Topline data readouts for the trials are expected in the first quarter of 2027 and mid-2027, respectively.

 

  •  

On July 21, 2026, the Company announced an exclusive distribution, marketing and supply agreement with Medomie Pharma Ltd. regarding commercial rights for YCANTH for the treatment of molluscum contagiosum in Israel. The Company is working with Medomie to support their regulatory filing in Israel.

VP-315

 

  •  

On September 10 and 30, 2026, the Company announced encore poster presentations at various scientific meetings.

 

  •  

The Company is now exploring VP-315 for the treatment of patients with Gorlin syndrome, leveraging the extensive data from the completed Phase 2 study in sporadic BCC to this patient population with high disease burden and surgical fatigue, with no current FDA-approved products available for this indication. The Company is evaluating the potential study design and associated trial budget, and will update its business plan upon finalizing any study of VP-315 for the treatment of Gorlin syndrome


Corporate

 

  •  

On October 22, 2026, the Company announced achievement of milestones unlocking access to the remaining $15.0 million of non-dilutive growth capital under its $27.5 million credit facility with an entity controlled by Paul B. Manning, the Company’s Chairman and largest shareholder. With this additional borrowing capacity, based on the Company’s current business plan, the Company believes that its cash runway will extend into the fourth quarter of 2027, without giving effect to any potential clinical trial costs related to the study of VP-315 for the treatment of Gorlin syndrome.

Financial Results

Third Quarter 2026 Financial Results

 

  •  

Total revenue for the three months ended September 30, 2026, was $6.9 million compared to total revenue of $14.3 million for the three months ended September 30, 2025, which included a $10.0 million one-time milestone payment from Torii Pharmaceutical Co., Ltd., Verrica’s Japanese development partner.

 

  •  

U.S. YCANTH product revenue, net was $5.7 million for the quarter ended September 30, 2026, compared to net product revenue of $3.6 million for the quarter ended September 30, 2025. The increase in product revenue, net, was primarily related to increased deliveries of YCANTH to our distribution partners as well as improved yield from reduced spending on our co-pay assistance program.

 

  •  

License and collaboration revenue was $1.2 million for the quarter ended September 30, 2026, consisting primarily of commercial supply for Torii’s YCANTH launch in Japan, compared to license and collaboration revenue from Torii of $10.7 million for the three months ended September 30, 2025, which included $10.0 million of one-time milestone revenue, as well as $0.7 million of collaboration revenue for supplies and development activity with Torii.

 

  •  

Costs of product revenue were $0.6 million for the quarter ended September 30, 2026, compared to $0.8 million for the quarter ended September 30, 2025, consisting primarily of product costs related to the sale of YCANTH.

 

  •  

Selling, general and administrative expenses were $10.4 million for the quarter ended September 30, 2026, compared to $9.4 million for the same period in 2025. Excluding the impact of stock-based compensation, expenses were comparable to the prior period.

 

  •  

Research and development expenses were $7.6 million for the quarter ended September 30, 2026, compared to $2.2 million for the same period in 2025. Excluding the impact of stock-based compensation, the increase of $5.2 million was primarily attributable to an increase of $3.7 million in non-cash costs associated with the Phase 3 program for common warts, in addition to an increase of $1.3 million in expenses related to chemistry, manufacturing and controls across YCANTH and VP-315. The expense for the Phase 3 common warts program did not impact Verrica’s cash balance, as the first $40 million of payments for this program, representing approximately 90% of the current estimated study costs, will be made by Torii under the Company’s collaboration and license agreement.


  •  

Interest income was $45,000 for the quarter ended September 30, 2026, compared to $0.2 million for the quarter ended September 30, 2025. The decrease in interest income was primarily due to lower cash balances.

 

  •  

Interest expense was $0.3 million for the quarter ended September 30, 2026, compared to $2.1 million for the same period in 2025. The decrease of $1.8 million was related to the settlement and termination of the Company’s OrbiMed debt facility in November 2025, partially offset by imputed interest on the R&D funding liability and $0.1 million of interest expense on term loans borrowed under the Company’s new credit facility with an affiliate of Paul B. Manning, the Company’s Chairman and largest shareholder.

 

  •  

For the quarter ended September 30, 2026, net loss was $12.4 million, or $0.58 per share, compared to a net loss of $0.3 million, or $0.03 per share, for the same period in 2025.

 

  •  

For the quarter ended September 30, 2026, non-GAAP net loss was $10.5 million, or $0.49 per share, compared to a non-GAAP net income of $1.1 million, or $0.12 per share, for the same period in 2025.

Non-GAAP Financial Measures

In evaluating the operating performance of its business, Verrica’s management considers non-GAAP income (loss) from operations, non-GAAP net income (loss) and non-GAAP net income (loss) per share. These non-GAAP financial measures exclude stock-based compensation expense and non-cash interest expense that are required by GAAP. Verrica excludes non-cash stock-based compensation expense from these non-GAAP measures to facilitate comparison to peer companies who also provide similar non-GAAP disclosures and because it reflects how management internally manages the business. In addition, Verrica excludes non-cash interest expense from these non-GAAP measures to facilitate an understanding of the effects of the debt service obligations on the Company’s liquidity and comparisons to peer group companies who also provide similar non-GAAP disclosures and because it is reflective of how management internally manages the business. Non-GAAP income (loss) from operations, non-GAAP net income (loss) and non-GAAP net income (loss) per share should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. These measures have been reconciled to the nearest GAAP measure in the tables following the financial statements in this press release.

About YCANTH® (VP-102)

YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Please visit YCANTHPro.com for additional information.

YCANTH is now approved for the treatment of molluscum contagiosum in Japan based upon an additional Phase 3 trial of approximately 300 patients. YCANTH is being studied in a global Phase 3 program in the U.S. and Japan for use in the treatment of common warts.


About VP-315 (ruxotemitide)

VP-315 is a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy administered directly into a tumor to induce immunogenic cell death and thereby unleash a broad spectrum of tumor antigens for T cell responses, which may offer a non-surgical option for patients suffering from skin cancer. The technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Verrica holds an exclusive worldwide license to develop and commercialize VP-315 for certain dermatologic oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica has focused on basal cell and squamous cell carcinomas as the lead indications for development and is now exploring the development of VP-315 for the treatment of patients with Gorlin syndrome, a rare disease that causes recurrent basal cell carcinomas over the life of the patient. VP-315 has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 oncology trials.

About Verrica Pharmaceuticals Inc.

Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

About Dispensed Applicator Units

Dispensed applicator units represent applicators (a) shipped to healthcare professionals from Verrica’s contracted pharmacy partners for fulfillment, (b) sold by Verrica’s distribution partners to independent and regional pharmacies, and (c) sold to physician offices, hospitals and other clinics on a buy and bill basis.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about the Company’s future commercial growth for YCANTH, the timing of topline data in the COVE-2 and COVE-3 trials, the potential approval of YCANTH in common warts, Verrica’s ability to borrow additional funds under the credit facility, Verrica’s cash runway, potential future payments pursuant to the agreement with Medomie, the clinical development and potential benefits of Verrica’s product candidates, including YCANTH (VP-102) and the Company’s exploration of development plans for VP-315 in BCC or Gorlin syndrome. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2025, Verrica’s Quarterly Reports on Form 10-Q and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.


VERRICA PHARMACEUTICALS INC.

Selected Statements of Operations Data

(in thousands except share and per share data)

(unaudited)

 

     Three Months Ended September 30,  
     2026     2025  

Revenue

    

Product revenue, net

   $ 5,697     $ 3,607  

License and Collaboration revenue

     1,217       10,737  
  

 

 

   

 

 

 

Total revenue

     6,914       14,344  
  

 

 

   

 

 

 

Operating Expenses:

    

Cost of product revenue

     583       754  

Cost of collaboration revenue

     565       355  

Selling, general and administrative

     10,356       9,403  

Research and development

     7,577       2,205  
  

 

 

   

 

 

 

Total expenses

     19,081       12,717  
  

 

 

   

 

 

 

(Loss) income from operations

     (12,167 )      1,627  

Interest income

     45       159  

Interest expense

     (285 )      (2,094 ) 

Change in fair value of derivative liability

     —        34  
  

 

 

   

 

 

 

Net (loss) income

   $ (12,407 )    $ (274 ) 
  

 

 

   

 

 

 

Net (loss) income per share

    

Basic and diluted

   $ (0.58 )    $ (0.03 ) 
  

 

 

   

 

 

 

Weighted average common shares outstanding

    

Basic and diluted

     21,305,025       9,490,083  
  

 

 

   

 

 

 


VERRICA PHARMACEUTICALS INC.

Selected Statements of Operations Data

(in thousands except share and per share data)

(unaudited)

 

     Nine Months Ended September 30,  
     2026     2025  

Revenue

    

Product revenue, net

   $ 15,080     $ 11,563  

License and Collaboration revenue

     2,719       18,922  
  

 

 

   

 

 

 

Total revenue

     17,799       30,485  
  

 

 

   

 

 

 

Operating Expenses:

    

Cost of product revenue

     1,562       1,517  

Cost of collaboration revenue

     1,353       523  

Selling, general and administrative

     30,694       27,103  

Research and development

     17,471       6,335  

Legal settlement, net of insurance recovery

     1,698       —   
  

 

 

   

 

 

 

Total expenses

     52,778       35,478  
  

 

 

   

 

 

 

Loss from operations

     (34,979 )      (4,993 ) 

Interest income

     357       724  

Interest expense

     (609 )      (6,428 ) 

Change in fair value of derivative liability

     —        886  

Other expense

     (11 )      (1 ) 
  

 

 

   

 

 

 

Net loss

   $ (35,242 )    $ (9,812 ) 
  

 

 

   

 

 

 

Net loss per share

    

Basic and diluted

   $ (1.65 )    $ (1.03 ) 
  

 

 

   

 

 

 

Weighted average common shares outstanding

    

Basic and diluted

     21,305,025       9,489,173  
  

 

 

   

 

 

 


VERRICA PHARMACEUTICALS INC.

Selected Balance Sheets Data

(in thousands)

(unaudited)

 

     September 30,     December 31,  
   2026     2025  

Cash

   $ 14,394     $ 30,147  

Accounts receivable

     11,649       5,397  

Deferred R&D services, current portion

     1,491       1,958  

Insurance recovery asset

     2,333       —   

Inventory

     2,804       2,236  

Prepaid expenses and other assets

     3,728       2,801  
  

 

 

   

 

 

 

Total current assets

     36,399       42,539  

Deferred R&D services, non-current portion

     924       2,354  

PP&E, Lease right-of-use asset, other

     2,538       2,238  
  

 

 

   

 

 

 

Total assets

   $ 39,861     $ 47,131  
  

 

 

   

 

 

 

Legal settlement liability

   $ 4,000     $ —   

R&D funding liability

     10,940       5,066  

Term loans, net, related party

     11,636       —   

Other current and noncurrent liabilities

     19,259       17,322  
  

 

 

   

 

 

 

Total liabilities

     45,835       22,388  

Total stockholders’ (deficit) equity

     (5,974 )      24,743  
  

 

 

   

 

 

 

Total Liabilities & Stockholders’ (Deficit) Equity

   $ 39,861     $ 47,131  
  

 

 

   

 

 

 


VERRICA PHARMACEUTICALS INC.

Reconciliation of Non-GAAP Financial Measures (unaudited)

(in thousands, except share and per share data)

 

     Three Months Ended September 30,
2026
 
     Loss from
Operations
     Net loss      Net loss
per share
(basic and
diluted)
 

GAAP

   $ (12,167 )     $ (12,407 )     $ (0.58 ) 

Non-GAAP Adjustments:

        

Stock-based compensation - Selling, General & Admin (a)

     1,420        1,420        0.07  

Stock-based compensation - Research & Development (a)

     465        465        0.02  

Stock-based compensation - Cost of Product (a)

     11        11        0.00  

Stock-based compensation - Cost of Collaboration (a)

     11        11        0.00  

Non-cash interest expense (b)

     —         4        0.00  
  

 

 

    

 

 

    

 

 

 

Adjusted

   $ (10,260 )     $ (10,496 )     $ (0.49 ) 
  

 

 

    

 

 

    

 

 

 

 

(a)

The effects of non-cash stock-based compensation are excluded because of varying available valuation methodologies and subjective assumptions. Verrica believes this is a useful measure for investors because such exclusion facilitates comparison to peer companies who also provide similar non-GAAP disclosures and is reflective of how management internally manages the business.

(b)

The effects of non-cash interest expenses and legal settlement, net of insurance recovery are excluded because Verrica believes such exclusions facilitate comparisons to peer group companies and is reflective of how management internally manages the business.


VERRICA PHARMACEUTICALS INC.

Reconciliation of Non-GAAP Financial Measures (unaudited)

(in thousands, except share and per share data)

 

     Three Months Ended September 30, 2025  
     Income from
Operations
     Net (loss)
income
     Net (loss)
income per
share
 

GAAP

   $ 1,627      $ (274 )     $ (0.03 ) 

Non-GAAP Adjustments:

        

Stock-based compensation - Selling, General & Admin (a)

     431        431        0.05  

Stock-based compensation - Research & Development (a)

     287        287        0.03  

Derivative liability change in value (b)

     —         (34 )       (0.00 ) 

Non-cash interest expense (b)

     —         716        0.08  
  

 

 

    

 

 

    

 

 

 

Adjusted

   $ 2,345      $ 1,126      $ 0.12  
  

 

 

    

 

 

    

 

 

 

 

(a)

The effects of non-cash stock-based compensation are excluded because of varying available valuation methodologies and subjective assumptions. Verrica believes this is a useful measure for investors because such exclusion facilitates comparison to peer companies who also provide similar non-GAAP disclosures and is reflective of how management internally manages the business.

(b)

The effects of non-cash interest expenses and derivative liability change in value are excluded because Verrica believes such exclusions facilitate an understanding of the effects of the debt service obligation on the Company’s liquidity and comparisons to peer group companies and is reflective of how management internally manages the business.


VERRICA PHARMACEUTICALS INC.

Reconciliation of Non-GAAP Financial Measures (unaudited)

(in thousands, except share and per share data)

 

     Nine Months Ended September 30, 2026  
     Loss from
Operations
     Net loss      Net loss
per share
(basic and
diluted)
 

GAAP

   $ (34,979 )     $ (35,242 )     $ (1.65 ) 

Non-GAAP Adjustments:

        

Stock-based compensation - Selling, General & Admin (a)

     2,812        2,812        0.13  

Stock-based compensation - Research & Development (a)

     1,137        1,137        0.05  

Stock-based compensation - Cost of Product (a)

     33        33        0.00  

Stock-based compensation - Cost of Collaboration (a)

     35        35        0.00  

Legal settlement, net of insurance recovery (b)

     1,698        1,698        0.08  

Non-cash interest expense (b)

     —         4        0.00  
  

 

 

    

 

 

    

 

 

 

Adjusted

   $ (29,264 )     $ (29,523 )     $ (1.39 ) 
  

 

 

    

 

 

    

 

 

 

 

(a)

The effects of non-cash stock-based compensation are excluded because of varying available valuation methodologies and subjective assumptions. Verrica believes this is a useful measure for investors because such exclusion facilitates comparison to peer companies who also provide similar non-GAAP disclosures and is reflective of how management internally manages the business.

(b)

The effects of non-cash interest expenses and legal settlement, net of insurance recovery are excluded because Verrica believes such exclusions facilitate an understanding of the effects of the debt service obligation on the Company’s liquidity and comparisons to peer group companies and is reflective of how management internally manages the business.


     Nine Months Ended September 30, 2025  
     Loss from
Operations
     Net loss      Net loss
per share
 

GAAP

   $ (4,993 )     $ (9,812 )     $ (1.03 ) 

Non-GAAP Adjustments:

        

Stock-based compensation - Selling, General & Admin (a)

     1,804        1,804        0.19  

Stock-based compensation - Research & Development (a)

     828        828        0.09  

Derivative liability change in value (b)

        (886 )       (0.09 ) 

Non-cash interest expense (b)

        2,075        0.22  
  

 

 

    

 

 

    

 

 

 

Adjusted

   $ (2,361 )     $ (5,991 )     $ (0.63 ) 
  

 

 

    

 

 

    

 

 

 

 

(a)

The effects of non-cash stock-based compensation are excluded because of varying available valuation methodologies and subjective assumptions. Verrica believes this is a useful measure for investors because such exclusion facilitates comparison to peer companies who also provide similar non-GAAP disclosures and is reflective of how management internally manages the business.

(b)

The effects of non-cash interest expenses and derivative liability change in value are excluded because Verrica believes such exclusions facilitate an understanding of the effects of the debt service obligation on the Company’s liquidity and comparisons to peer group companies and is reflective of how management internally manages the business.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

John Kirby

Interim Chief Financial Officer

jkirby@verrica.com

Kevin Gardner

LifeSci Advisors

kgardner@lifesciadvisors.com

Filing Exhibits & Attachments

4 documents

Keep reading